Inhaled treprostinil: a therapeutic review
Open Access
- 1 January 2012
- journal article
- review article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 6, 19-28
Abstract
Peer reviewed article authored by (Channick RN, Voswinckel R, Rubin LJ). Read article or submit your manuscript for publishing.Keywords
This publication has 29 references indexed in Scilit:
- Tadalafil Therapy for Pulmonary Arterial HypertensionCirculation, 2009
- Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial HypertensionJACC, 2009
- Ambrisentan for the Treatment of Pulmonary Arterial HypertensionCirculation, 2008
- Sildenafil Citrate Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2005
- Inhaled Iloprost for Severe Pulmonary HypertensionNew England Journal of Medicine, 2002
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension: A Double-blind, Randomized, Placebo-controlled TrialAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Survival in Patients with Primary Pulmonary HypertensionAnnals of Internal Medicine, 1991